Cargando…
Bleeding management: rFVIIIFc in hemophilia A and liver transplantation
BACKGROUND: In patients with severe hemophilia A prolonged bleeding may occur even in cases of minor trauma or surgery. OBJECTIVE: To investigate the feasibility and efficacy of a recombinant extended half-life (EHL) FVIII concentrate for perioperative bleeding management in a patient with severe he...
Autores principales: | Grottke, Oliver, Rieg, Annette, Ulmer, Florian, Hein, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692241/ https://www.ncbi.nlm.nih.gov/pubmed/37563315 http://dx.doi.org/10.1007/s00101-023-01320-1 |
Ejemplares similares
-
Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
por: Krishnamoorthy, Sriram, et al.
Publicado: (2015) -
First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results
por: Königs, Christoph, et al.
Publicado: (2022) -
Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States
por: Bullement, Ash, et al.
Publicado: (2021) -
Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials
por: Klamroth, Robert, et al.
Publicado: (2021) -
Improvement in pain-related quality of life in patients with
hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis
from the A-LONG study
por: Pasi, John, et al.
Publicado: (2022)